# US 2004/0082003 A1 · Stem cell expansion enhancing factor and method of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082003 A1
- Document ID: US20040082003A1
- Status: Published application
- Kind: A1
- Application number: 10/727,580
- Filed: 2003-12-05
- Published: 2004-04-29
- Earliest claimed: 2000-02-23
- Inventors: Guy Sauvageau; Richard Keith Humphries
- Web page: https://patentgrep.com/patent/US20040082003A1

## CPC

- C07K 14/475: Growth factors; Growth regulators
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2501/125: Stem cell factor [SCF], c-kit ligand [KL]
- C12N 2501/23: Interleukins [IL]
- C12N 2501/60: Transcription factors
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a stem cell expansion factor, and to a method for enhancing hematopoietic stem cell expansion by direct delivery of a protein in the cell and which protein is able to cross cell membrane. The method comprises directly delivering in a HSC an amino acid sequence having the activity of a peptide encoded by a Hoxb4 nucleotide sequence. Once delivered, the amino acid sequence is functionally active in the hematopoietic stem cell and enhances expansion thereof. The amino acid sequence may is a HOXB4 or HOXA4 protein.

## Claims

### Claim 1

A stem cell expansion factor, which comprises an amino acid sequence having the expansion enhancement activity of a peptide encoded by a Hox nucleotide sequence enhancing expansion of a stem cell population, and wherein said amino acid sequence is able to cross a cell membrane.

### Claim 2 (depends on 1)

The factor according to claim 1, wherein said amino acid sequence is a HOXB4 or HOXA4 protein.

### Claim 3 (depends on 1)

The factor according to claim 1, wherein said amino acid sequence further comprises an HIV-derived peptide able to cross a cell membrane.

### Claim 4 (depends on 3)

The factor according to claim 3, wherein said HIV-derived peptide consists of a NH2-terminal protein transduction domain (PTD) from a transactivating protein (TAT).

### Claim 5 (depends on 4)

The factor according to claim 4, wherein said stem cell is a hematopoietic stem cell.

### Claim 6 (depends on 5)

The factor according to claim 5, wherein said hematopoietic stem cell is human or mouse.

### Claim 7 (depends on 1)

A method for enhancing expansion of a stem cell population, the method comprising directly delivering in a stem cell population an effective amount of the stem cell expansion factor of claim 1, whereby said amino acid sequence is able to cross a cell membrane and is substantially active in said stem cell population, thereby enhancing expansion of said stem cell population.

### Claim 8 (depends on 7)

A method according to claim 7, wherein said amino acid sequence is a HOXB4 or HOXA4 protein.

### Claim 9 (depends on 7)

A method according to claim 7, wherein the amino acid sequence is delivered in said stem cell population in vivo.

### Claim 10 (depends on 7)

A method according to claim 7, wherein said amino acid sequence further comprises an HIV-derived peptide able to cross a cell membrane.

### Claim 11 (depends on 10)

A method according to claim 10, wherein said HIV-derived peptide consists of a NH2-terminal protein transduction domain (PTD) from a transactivating protein (TAT).

### Claim 12 (depends on 11)

A method according to claim 11, wherein said stem cell is a hematopoietic stem cell.

### Claim 13 (depends on 12)

A method according to claim 12, wherein said hematopoietic stem cell is human.

### Claim 14

A drug-inducible method for enhancing expansion of a stem cell population, the method comprising:
a) delivering in a stem cell population a nucleotide sequence linked to a drug-binding protein and encoding one of a DNA-binding domain and a NH2-terminal domain of a peptide having the activity of a Hox protein able to enhance expansion of said stem cell population, delivering in said stem cell population a nucleotide sequence encoding the remainder of the DNA-binding domain and N-terminal domains linked to a drug-binding protein; and
b) exposing said stem cell to a dimerizing agent;
whereby a functionally active protein is reconstituted in said stem cell population, thereby enhancing expansion of said stem cell.

### Claim 15 (depends on 14)

A method according to claim 14, wherein said drug-binding protein consists of FKBP12, and wherein said dimerizing agent consists of FK1012 or an analog thereof.

### Claim 16 (depends on 15)

A method according to claim 15, wherein said stem cell is a hematopoietic stem cell.

### Claim 17 (depends on 16)

A method according to claim 16, wherein said hematopoietic stem cell is human.

### Claim 18 (depends on 1)

A method for restoring a patient hematopoietic capability, said method comprising directly delivering in a hematopoietic stem cell population of a patient the stem cell expansion factor of claim 1, wherein said amino acid sequence is able to cross a cell membrane and is substantially active in said hematopoietic stem cell, thereby enhancing expansion of said hematopoietic stem cell population and restoring hematopoietic capability of said patient.

### Claim 19 (depends on 18)

A method according to claim 18, wherein said amino acid sequence is a HOXB4 or HOXA4 peptide.

### Claim 20 (depends on 18)

A method according to claim 18, wherein said amino acid sequence is delivered in said hematopoietic stem cell in vivo.

### Claim 21 (depends on 18)

A method according to claim 18, wherein said amino acid sequence further comprises an HIV-derived peptide able to cross a cell membrane.

### Claim 22 (depends on 21)

A method according to claim 21, wherein said HIV-derived peptide consists of a NH2-terminal protein transduction domain (PTD) from a transactivating protein (TAT).

### Claim 23 (depends on 19)

A method according to claim 19, wherein said hematopoietic stem cell is human.

### Claim 24 (depends on 1)

A composition comprising a hematopoietic stem cell population having enhanced expansion capability, said hematopoietic stem cell population being generated by directly delivering therein the stem cell expansion factor of claim 1 and which is functionally active therein, in association with a pharmaceutically acceptable carrier.

### Claim 25 (depends on 1)

The factor according to claim 1, wherein said amino acid sequence is a HOXC4 or HOXD4 protein.
